Year All202620252024202320222021202020192018201720162014201320112010 January 4, 2024 Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640 January 4, 2024 Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates December 15, 2023 Rhythm Pharmaceuticals Announces New Employment Inducement Grants December 13, 2023 Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023 December 6, 2023 Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event November 13, 2023 Rhythm Pharmaceuticals Announces New Employment Inducement Grants November 7, 2023 Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update November 2, 2023 Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide) October 25, 2023 Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 October 17, 2023 Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
January 4, 2024 Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
January 4, 2024 Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
December 13, 2023 Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
November 7, 2023 Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
November 2, 2023 Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)
October 25, 2023 Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 17, 2023 Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
